These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 812650)

  • 1. Procainamide in acute myocardial infarction: a study on two different tablet preparations of sustained release type.
    Ihlen H; Ditlefsen L
    Curr Ther Res Clin Exp; 1975 Nov; 18(5):720-6. PubMed ID: 812650
    [No Abstract]   [Full Text] [Related]  

  • 2. Procainamide in plasma following administration of sustained-release tablets in acute myocardial infarction.
    Ihlen H; Skomedal T; Stafsnes H; Ditlefsen EM
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):257-62. PubMed ID: 805020
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
    Henningsen P; Laursen HB; Christiansen BD; Moller J
    Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
    [No Abstract]   [Full Text] [Related]  

  • 4. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma levels of procaine amide after administration of conventional and sustained-release tablets.
    Karlsson E
    Eur J Clin Pharmacol; 1973 Dec; 6(4):245-50. PubMed ID: 4591151
    [No Abstract]   [Full Text] [Related]  

  • 6. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 7. Control of procainamide therapy after cardiac infarction.
    Royds R; Shaw TR; Kumana CR; Padgham D; Hamer J
    Br Heart J; 1973 Aug; 35(8):862-3. PubMed ID: 4729848
    [No Abstract]   [Full Text] [Related]  

  • 8. A new sustained-release tablet formulation of procainamide.
    Fremstad D; Dahl S; Jacobsen S; Lunde PK; Nådland KJ; Marthinsen AA; Waaler T; Landmark KH
    Eur J Clin Pharmacol; 1973 Dec; 6(4):251-5. PubMed ID: 4591152
    [No Abstract]   [Full Text] [Related]  

  • 9. Sustained release procainamide in patients with myocardial infarction.
    Birkhead J; Evans T; Mumford P; Martinez E; Jewitt D
    Br Heart J; 1976 Jan; 38(1):77-80. PubMed ID: 1252299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML; Babich MF; Klinke WP; Hui WK
    Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure red cell aplasia associated with administration of sustained-release procainamide.
    Giannone L; Kugler JW; Krantz SB
    Arch Intern Med; 1987 Jun; 147(6):1179-80. PubMed ID: 3036033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting plasma procainamide concentrations resulting from a sustained-release preparation.
    DiPersio DM; Chow MS
    Clin Pharm; 1985; 4(2):186-91. PubMed ID: 3987218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procainamide, oxprenolol and amiodarone as antidysrhythmic drugs in myocardial infarction.
    Tuna JL; Correia MJ; d'Almeida VC; Mourão L; da Costa FL; Ribeiro C
    Acta Med Port; 1980 Dec; Suppl 1():27-32. PubMed ID: 6164252
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombocytopenia following sustained-release procainamide.
    Meisner DJ; Carlson RJ; Gottlieb AJ
    Arch Intern Med; 1985 Apr; 145(4):700-2. PubMed ID: 2580499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets.
    Arstila M; Katila M; Sundquist H; Anttila M; Pere E; Tikkanen R
    Acta Med Scand; 1974 Mar; 195(3):217-22. PubMed ID: 4595254
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceutical and pharmacokinetic principles in the formulation of a sustained-release procainamide tablet.
    Dahl SG; Fremstad D; Jacobsen S; Kvaleid I; Landmark KH; Lunde PK; Marthinsen AA; Nådland KJ; Waaler T
    Pharm Acta Helv; 1976; 51(7-8):204-8. PubMed ID: 967912
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of a new sustained release procainamide preparation: evaluation with 24-hour Holter monitoring.
    Garcia JR; Godley ML; Freedman RJ
    J La State Med Soc; 1982; 134(1):8-9. PubMed ID: 7086265
    [No Abstract]   [Full Text] [Related]  

  • 18. [Studies on a sustained release procainamide hydrochloride tablet--an oral osmotic pump].
    Zhu YP; Mao FF; Tu XD
    Yao Xue Xue Bao; 1988 Nov; 23(11):850-6. PubMed ID: 3257042
    [No Abstract]   [Full Text] [Related]  

  • 19. [Collective studies on the administration of procainamide in the prevention of early mortality in myocardial infarct].
    Kardiol Pol; 1976; 19(4):317-24. PubMed ID: 787614
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical use of procainamide.
    Miller RR; Greenblatt DJ
    Am J Hosp Pharm; 1974 Sep; 31(9):889-91. PubMed ID: 4607729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.